Infrared fluorescence for vascular barrier breach in vivo--a novel method for quantitation of albumin efflux.
Vascular hyperpermeability contributes to morbidity in inflammation. Current methodologies for  in vivo  assessment of permeability based on extravasation of Evans Blue (EB)-bound albumin are cumbersome and often lack sensitivity. We developed a novel infrared fluorescence (IRF) methodology for measurement of EB-albumin extravasation to quantify vascular permeability in murine models. Vascular permeability induced by endotoxaemia was examined for all solid organs, brain, skin and peritoneum by IRF and the traditional absorbance-based measurement of EB in tissue extracts. Organ IRF increased linearly with increasing concentrations of intravenous EB (2.5-25 mg/kg). Tissue IRF was more sensitive for EB accumulation compared to the absorbance-based method. Accordingly, differences in vascular permeability and organ EB accumulation between lipopolysaccharide-treated and saline-treated mice were often significant when analysed by IRF-based detection but not by absorbance-based detection. EB was detected in all 353 organs analysed with IRF but only in 67% (239/353) of organs analysed by absorbance-based methodology, demonstrating improved sensitivity of EB detection in organs with IRF. In contrast, EB in plasma after EB administration was readily measured by both methods with high correlation between the two methods (n=116, r2=0.86). Quantitation of organ-specific EB-IRF differences due to endotoxin was optimal when IRF was compared between mice matched for weight, gender, and age, and with appropriate corrections for organ weight and EB plasma concentrations. Notably, EB-IRF methodology leaves organs intact for subsequent histopathology. In summary, EB-IRF is a novel, highly sensitive, rapid, and convenient method for the relative quantification of EB in intact organs of treatment versus control mice.
Department of Medicine, University of California San Diego, San Diego, California, USA. avondrygalski@ucsd.edu
Annette
A
von Drygalski
Christian
C
Furlan-Freguia
Laurent O
LO
Mosnier
Subramanian
S
Yegneswaran
Wolfram
W
Ruf
John H
JH
Griffin
D000818:Animals; D002199:Capillary Permeability / Q000502:physiology*; D004396:Coloring Agents / Q000008:administration & dosage / Q000378:metabolism; D004195:Disease Models, Animal; D005070:Evans Blue / Q000008:administration & dosage / Q000378:metabolism*; D005260:Female; D006454:Hemoglobins / Q000378:metabolism; D007249:Inflammation / Q000097:blood / Q000209:etiology; D007259:Infrared Rays; D008070:Lipopolysaccharides / Q000633:toxicity; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D061848:Optical Imaging; D009928:Organ Specificity; D012709:Serum Albumin / Q000378:metabolism*
D004396:Coloring Agents; D006454:Hemoglobins; D008070:Lipopolysaccharides; D012709:Serum Albumin; D005070:Evans Blue